Advanced search×

Long-term results of definitive radiotherapy for stage I esophageal cancer

Int J Radiat Oncol Biol Phys 62(5):6 (2005) PMID 16029790

Purpose: To analyze retrospectively the long-term results of external beam radiotherapy (RT) with or without intraluminal brachytherapy (ILBT) for patients with Stage I esophageal cancer. Methods and Materials: A total of 34 patients with esophageal squamous cell carcinoma, clinically diagnosed as having Stage I disease, were treated with definitive RT, with or without ILBT. The median age was 69 years. Seven patients were treated with external beam RT alone (median, 64 Gy), and 27 were treated with external beam RT (median, 52 Gy) plus ILBT (8-12 Gy in two to three fractions). Results: The 5-year overall survival, local relapse-free survival, and cause-specific survival rate was 58.9%, 68.4%, and 80.0%, respectively, with a median follow-up of 61 months. Of 9 patients with local recurrence after initial therapy, 7 were successfully treated, and the 5-year cumulative rate of esophagectomy was 19.6%. The 2-year local relapse-free rate for patients with and without ILBT was 79.1% and 53.6%, respectively. Conclusion: Although local recurrence was frequent within 2 years, the disease-specific survival rate was high owing to effective salvage therapy. Definitive RT is a reasonable treatment option for highly comorbid and elderly patients with Stage I esophageal cancer. The role of ILBT needs to be clarified.

DOI: 10.1016/j.ijrobp.2004.12.042
Version: za2963e q8za6 q8zb1 q8zca q8zd1 q8ze0 q8zf2 q8zg9

Similar articles you may find interesting…

  1. Prediction models: revolutionary in principle, but do they do more good than harm?

    J Clin Oncol 29(22):2951-2 (2011) PMID 21690474

  2. Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal carcinoma

    Int J Radiat Oncol Biol Phys 64(4):6 (2006) PMID 16504758

    The 5-year overall and cause-specific and disease-free survival rates were 66.4%, 76.3%, and 63.7%, respectively. The 5-year cause-specific survival rates for T1a and T1b cancer patients were 85.2% and 70.0%, respectively (p = 0.06). The 5-year disease-free survival rates for T1a and T1b were 84.4%...
  3. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases.

    Ann Surg Oncol 16(7):1844-51 (2009) PMID 19224284

    Response to neoadjuvant chemotherapy did not correlate with OS even after controlling for margins, stage of primary tumor, and postoperative carcinoembryonic antigen level. Postoperative salvage treatment may have helped the survival of some patients....